Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24230026 | 0.95 | CA12 (0.59) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL26366693 | 0.95 | CA12 (0.59) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230319 | 0.95 | CA12 (0.59) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230437 | 0.93 | CA12 (0.64) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230347 | 0.90 | CA12 (0.58) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230400 | 0.88 | CA12 (0.59) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230491 | 0.85 | CA12 (0.56) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230351 | 0.83 | CA12 (0.55) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL24230441 | 0.82 | CA12 (0.54) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL21711170 | 0.82 | MEN1 (0.61) | CA12CA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022026756-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | ST. JOHN'S CANCER INSTITUTE (US) | 2022-02-03 | — | — | WO | disclosed |
| US-7173021-B2 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2007-02-06 | — | — | US | disclosed |
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TIANJIN NORTH PHARM SCI-TECH CO., LTD. (CN) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047117-A1 | Synthesis of temozolomide esters as potent anticancer pro-drugs for topical and transdermal applications in treatments of cancers | TET1, SLC16A1, ADH1A | CA12 71/4885CA1 147/4885CA2 1321/4885 |
| US-20230303577-A1 | TEMOZOLOMIDE ANALOGS AND METHODS OF USE | MGMT, TOP2B, IDH3B | CA12 1312/4885CA1 1243/4885CA2 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.